ArticleAmerican journal of cancer research2016
Low expression of RBMS3 and SFRP1 are associated with poor prognosis in patients with gastric cancer.
Article in American journal of cancer research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 38 citations in OpenAlex.
- Article
- Role of the RBMS Family in Different Cancers and Research Progress.International journal of medical sciences · 2026Review
- RBM3-associated germline variants and their functional role in gastric cancer susceptibility and progression.Frontiers in oncology · 2026Article
- Function and Mechanism of the RNA-binding Protein RBMS3 in Malignant Tumours.Cell biochemistry and biophysics · 2025Review
- M6A-ALKBH5-dependent RBMS3-AS3 down-regulation suppresses ferroptosis to promote lung adenocarcinoma progression through HNRNPDL/ZEB1/GPX4 axis.NPJ precision oncology · 2025Article
- Stemness-based gastric cancer classification by machine learning for precision diagnosis and treatment of gastric cancer.Journal of gastrointestinal oncology · 2025Article
- Deciphering the tumor-suppressive role of RBMS3 in lung adenocarcinoma through genomic insights into prognosis and mechanisms.Scientific reports · 2025Article
- 1-L Transcription in Prion Diseases.International journal of molecular sciences · 2024Article
- Adipocytes impact on gastric cancer progression: Prognostic insights and molecular features.World journal of gastrointestinal oncology · 2024Article
- Tumor suppressor function of RBMS3 overexpression in EOC associated with immune cell infiltration.Heliyon · 2024Article
- The RNA-binding protein RBMS3 inhibits the progression of colon cancer by regulating the stability of LIMS1 mRNA.Cancer medicine · 2024Article
- Article
- TRIM69 suppressed the anoikis resistance and metastasis of gastric cancer through ubiquitin‒proteasome-mediated degradation of PRKCD.Oncogene · 2023Article
- RBMS3-induced circHECTD1 encoded a novel protein to suppress the vasculogenic mimicry formation in glioblastoma multiforme.Cell death & disease · 2023Article
- Expression of RBMS3 in Breast Cancer Progression.International journal of molecular sciences · 2023Article
- Role of RBMS3 Novel Potential Regulator of the EMT Phenomenon in Physiological and Pathological Processes.International journal of molecular sciences · 2022Review
- Genome-Wide Analyses of Nephrotoxicity in Platinum-Treated Cancer Patients Identify Association with Genetic Variant inJournal of personalized medicine · 2022Article
- RBMS1 promotes gastric cancer metastasis through autocrine IL-6/JAK2/STAT3 signaling.Cell death & disease · 2022Article
- Aberrant expression of SFRP1, SFRP3, DVL2 and DVL3 Wnt signaling pathway components in diffuse gastric carcinoma.Oncology letters · 2021Article
- RNA binding protein RBMS3 is a common EMT effector that modulates triple-negative breast cancer progression via stabilizing PRRX1 mRNA.Oncogene · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RNA binding motif, single stranded interacting protein 3 (RBMS3) has been reported as a tumor suppressor gene (TSG) in some squamous carcinoma. However, its expression levels and clinical significance in gastric cancer (GC) remains unclear. Secreted frizzled-related protein 1 (SFRP1) plays a role of tumor suppressor in many cancers by inhibiting Wnt/β-catenin pathway. Nevertheless, its expression levels and clinical significance in GC are in dispute. In this study, quantitative real-time PCR and Western Blot were used to measure the mRNA and protein level of RBMS3 and SFRP1 in 23 fresh GC and corresponding normal tissues. Immunohistochemistry assay was performed to further measure the protein level of RBMS3 and SFRP1 on population-based tissue microarrays consisting of 172 GC cases. We found that 69.57% (16/23) and 73.91% (17/23) GC tissues expressed remarkably lower RBMS3 than the matched normal tissues respectively in mRNA and protein levels. Similarly, 78.26% (18/23) and 65.22% (15/23) GC tissues expressed lower SFRP1 than the matched normal tissues respectively in mRNA and protein levels. Additionally, the low expression of RBMS3 and SFRP1 protein were all significantly related to the poor histological grades and prognosis (all P<0.05). In multivariate analysis, RBMS3 and SFRP1 co-expression status was independent prognostic factor for GC patients. Finally, the positive correlation between expression levels (mRNA and protein) of RBMS3 and SFRP1 was observed. Overall, RBMS3 and SFRP1 are both aberrantly low expressed in GC, and RBMS3 and SFRP1 co-expression is a potential prognosis predictor of GC.
Indexed as
Identifiers
27904780PMC5126282W2560844611What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.